ClinicalTrials.gg
RecruitingNCT07475572Updated Aug 24, 2026

Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma

A Phase 1 interventional study of AVT32-DRL_PB and Keytruda in Melanoma, sponsored by Alvotech Swiss AG. Recruiting at 1 site in Ukraine. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Alvotech Swiss AG · Phase 1, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Melanoma with a site in Ukraine — 4 open to participants now, 7 under way, 3 of them phase 3. Melanoma · Ukraine.

Planned enrollment
19th of 23
120 · median 272
Started
2026
with 1 other
Phase 1
7 of 23
2 open now
Registered
22nd of 23
by date
Lead sponsor
1 of 23
Alvotech Swiss AG

Among the 23 studies in Melanoma with a site in Ukraine, this one is the 19th largest by planned enrollment, is one of 2 that started in 2026, is one of 7 in phase 1, and was the 22nd registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

4 of the 23 studies in Melanoma with a site in Ukraine are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Melanoma with a site in Ukraine, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, parallel-group, 2 treatment group, repeated dose study to compare the PK, efficacy, safety, and immunogenicity of AVT32-DRL_PB (proposed Keytruda® biosimilar) versus Keytruda (pembrolizumab) when administered as monotherapy in participants with fully resected Stage IIB/C or Stage III melanoma requiring adjuvant treatment with pembrolizumab. Eligible participants will be randomized in a 1:1 ratio to the AVT32-DRL_PB or Keytruda treatment group and stratified by sex (female versus male) and body weight category (≤75 kg versus >75 kg). Study treatments will be administered every 3 weeks (Q3W) as an intravenous (IV) infusion over 30 minutes (1 administration Q3W is 1 treatment cycle). The administered pembrolizumab dose will be 200 mg Q3W for both treatment groups.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants (male/female) ≥18 years of age at the time of signing the ICF.
  • Have an (ECOG) performance status (PS) of 0 or 1 at the time of enrollment.
  • Participants with Stage IIB, IIC, or III confirmed cutaneous melanoma

Exclusion criteria

Exclusion Criteria:

  • Have had a solid organ transplant or bone marrow (stem cell) transplant that used donor stem cells (allogenic).
  • Has received prior systemic anticancer therapy for melanoma including agents.
  • Participants with a history of mucosal or uveal melanoma, even if diagnosis and treatment were completed >5 years ago.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    AVT32-DRL_PB

    AVT32-DRL\_PB will be administered during double blind period and open label period

    Biological: AVT32-DRL_PB

  • Active comparator
    Keytruda

    Keytruda will be administered during double blind period

    Biological: Keytruda

Interventions

  • BiologicalAVT32-DRL_PB

    AVT32-DRL\_PB at a dose 200 mg administered intravenously every 3 weeks.

  • BiologicalPembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Keytruda at a dose 200 mg administered intravenously every 3 weeks.

06

What researchers measure

Primary outcomes

  1. To demonstrate PK similarity of AVT32-DRL_PB versus Keytruda (pembrolizumab)

    AUC0-3w (Cycle 1)

    Time frame: Cycle 1 (each cycle is 21 days)

  2. To demonstrate PK similarity of AVT32-DRL_PB versus Keytruda (pembrolizumab)

    AUCtau,ss (Cycle 6)

    Time frame: Cycle 6 (each cycle is 21 days)

07

Study locations

1 of 1 sites recruiting
  • Site number 07010
    Kiev, Ukraine
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Oct 2027, 14 months after the start.

Of 226 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's planned 14 months is below that.

Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2026
First posted
Mar 16, 2026
StartActual
Aug 10, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Apr 14, 2028
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07475572
Lead sponsor
Alvotech Swiss AG
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
Aug 10, 2026
Primary completion
Oct 2027 (estimated)
Completion
Apr 14, 2028 (estimated)
Last update
Aug 24, 2026

Study contacts

Clinical Development Lead
Contact
alvotech.clinical@alvotech.com
+41 78 659 8989

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion